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Abstract
Background: Protease-activated receptors (PAR) are seven transmembrane G-coupled receptors
comprising four genes (PAR-1 ~ PAR-4). Mast cell has been identified to be able to express PARs
and release an array of cytokines upon activation. Recently, it was reported that interleukin (IL)-12
could regulate the expression of PARs in mast cells, and tryptase could induce IL-4 and IL-6 release
from mast cells. In order to further investigate the issues, RNA interference (RNAi) technique was
employed and small interfering RNAs (siRNA) of PARs were transfected in P815 cells.
Results: The results showed that siRNAs for PAR-1, PAR-2 and PAR-4 significantly downregulated
expression of PAR-1, PAR-2 and PAR-4 mRNAs and proteins in P815 cells at 24, 48 and 72 h
following transfection. siRNA PAR-1.2 and siRNA PAR-4.2 significantly reduced IL-12 induced
upregulation of PAR-1 and PAR-4 expression, respectively when P815 cells were transfected with
them for 48 h. siRNA PAR-2.3 blocked IL-12 induced downregulation of PAR-2 expression on both
mRNA and protein levels. It was also observed that siRNA PAR-2.3 and siRNA PAR-1.2 reduced
trypsin induced IL-4 release by approximately 92.6% and 65.3%, and SLIGKV-NH2 induced IL-4
release by 82.1% and 60.1%, respectively. Similarly, siRNA PAR-2.3 eliminated tryptase-induced IL-
4 release by 75.3%, and siRNA PAR-1.2 diminished SFLLR-NH2 induced IL-4 release by 79.3%.
However, siRNA PAR-1.2, siRNA PAR-2.3 and siRNA PAR-4.3 at 10 nM did not show any effect
on tryptase-induced IL-6 release from P815 cells.
Conclusion: In conclusion, siRNAs of PARs can modulate PAR expression and PAR related
cytokine production in mast cells, confirming that PARs are likely to play a role in allergic reactions.
Background
As the primary effector cell, mast cell is actively involved
in the pathogenesis of both acute and chronic allergic dis-
eases[1,2]. Upon activation, mast cell can release not only
its preformed but also newly generated mediators to fulfill
its biological functions. Besides histamine, heparin and
proteases, mast cells can synthesize and secrete a variety of
cytokines[2] such as IL-4, IL-5 and IL-6. These cytokines
have been well documented for their ability to regulate
cell behavior including growth, secretion and migration
in physiological and pathological conditions.
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In recent years, PARs have been indentified as receptors
for serine proteinases. PARs are a subfamily of seven trans-
membrane G-protein-coupled receptors. Among them,
PAR-1, PAR-3 and PAR-4 serve as a receptor of
thrombin[3-5]; PAR-1, PAR-2 and PAR-4 are receptors of
trypsin and PAR-2 is a receptor of tryptase. These serine
proteinases have been discovered to play a crucial role in
allergic inflammation. Tryptase was reported to be able to
stimulate microvascular leakage in the skin of guinea
pigs[6], to induce inflammatory cell accumulation in the
peritoneum of mice[7], to elicit histamine release from
mast cells6 and to enhance monocyte chemoattractant
protein-1 (MCP-1) and IL-8 production in human
endothelial cells[8]. Trypsin was found to be able to
induce histamine release from human tonsil and skin
mast cells[9] and to stimulate IL-8 and IL-6 release from
human respiratory epithelial cells[10].
RNAi is a process in which double-stranded RNA (dsRNA)
induces the posttranscriptional degradation of homolo-
gous transcripts. It has been observed in variety of organ-
isms including plants, fungi, insects, protozans and
mammals[11,12]. RNAi can be initiated by exposing cells
to dsRNA either via transfection or endogenous expres-
sion. dsRNAs are processed into 21- to 23-nt double-
stranded fragments known as siRNAs[12]. With unprece-
dented speed, RNAi has advanced from its basic discovery
in lower organisms to becoming a powerful genetic tool in
mammals. The aim of this study is to investigate the effect
of PAR-1, PAR-2 and PAR-4 gene silencing on the expres-
sion of PARs and cytokine production in P815 cells by
using RNAi.
Results
Reduction of PAR-1 expression in P815 cells by siRNA
Three target sequences in the coding region of PAR-1
mRNA were selected as siRNA sequences, namely siRNA
PAR-1.1, siRNA PAR-1.2 and siRNA PAR-1.3. Among the
3 siRNA PAR-1s, siRNA PAR-1.2 appeared most effective
in inhibition of PAR-1 mRNA expression in P815 cells
(data not shown). Approximately up to 80.5% reduction
of PAR-1 mRNA expression was observed when P815 cells
were transfected with 10 nM of siRNA PAR-1.2 for 48 h. At
24 or 72 h following transfection, however siRNA PAR-1.2
showed less degree of inhibition of PAR-1 mRNA expres-
sion (Figure 1A). Flow cytometry analysis revealed that
PAR-1 protein expression was eliminated by up to 60.1%
when P815 cells were transfected with 10 nM of siRNA
PAR-1.2 for 48 h (Figure 1B). Because siRNA PAR-1.2
showed greater inhibitory effect on PAR-1 expression at
48 h than at 24 or 72 h following incubation, the 48 h
incubation period was chosen as the fixed time point for
the following Western blot and immunofluorescent anal-
ysis. Approximately up to 46.3% and 42.6% inhibition of
PAR-1 expression was observed by Western blot (Figure
1C) and immunofluorescent analysis (Figure 1D), respec-
tively. siRNA PAR-1.1 and siRNA PAR-1.3 also showed
significant inhibition of PAR-1 protein expression in P815
cells (data not shown).
Reduction of PAR-2 expression in P815 cells by siRNA
Of the three siRNA PAR-2s, siRNA PAR-2.1 and PAR-2.3,
but not PAR-2.2 downregulated PAR-2 mRNA expression
by up to 69.3% and 82.1% at 48 h following transfection
(Figure 2A). Therefore siRNA PAR-2.3 was employed as a
representative throughout the study. siRNA PAR-2.3 also
suppressed PAR-2 protein expression during flow cytome-
try, Western blot and immunofluorescence staining anal-
ysis by up to 56.8% (Figure 2B), 60.2% (Figure 2C) and
59.3% (Figure 2D), respectively following 48 h incuba-
tion period. At 24 and 72 h following incubation, siRNA
PAR-2.3 showed significant downregulation of PAR-2
expression on both mRNA and protein levels.
Reduction of PAR-4 expression in P815 cells by siRNA
All three siRNAs of PAR-4, namely siRNA PAR-4.1, siRNA
PAR-4.2 and siRNA PAR-4.3 were able to downregulate
the PAR-4 expression on both mRNA and protein levels in
P815 cells (data not shown). However, siRNA PAR-4.3
showed the most potent effect on P815 cells among the 3
siRNAs. It was observed that siRNA PAR-4.3 suppressed
approximately up to 91.2% PAR-4 mRNA expression at 24
and 48 h following transfection (Figure 3A). siRNA PAR-
4.3 inhibited also up to 82.3% PAR-4 protein expression
on flow cytometry analysis at 72 h (Figure 3B). Similarly,
siRNA PAR-4.3 eliminated PAR-4 expression by 52.3 and
91.3% on Western blot (Figure 3C) and immunofluores-
cence staining analysis (Figure 3D) in P815 cells at 48 h
following transfection.
Inhibition of IL-12 induced changes in PAR expression in 
P815 cells by siRNA
IL-12 at the concentration of 10 ng/ml induced approxi-
mately 2.4 and 3.0 fold upregulation of expression of
PAR-1 (Figure 4A) and PAR-4 mRNAs (Figure 4C) in P815
cells, respectively at 6 h following incubation. In contrast,
10 ng/ml of IL-12 downregulated PAR-2 mRNA expres-
sion in P815 cells by approximately up to 40.1% (Figure
4B). It was observed that IL-12 induced upregulation of
PAR-4 (Figure 4E), but downregulation of PAR-2 protein
expression (Figure 4D). siRNA PAR-1.2 at 10 nM and
siRNA PAR-4.2 at 10 nM significantly reduced IL-12
induced upregulation of PAR-1 (Figure 4A) and PAR-4
expression (Figure 4C, Fig. 4E), respectively when P815
cells were transfected with them for 48 h. siRNA PAR-2.3
at 10 nM was able to block IL-12 induced downregulation
of PAR-2 expression on both mRNA (Figure 4B) and pro-
tein (Figure 4D) levels in P815 cells.
Inhibition of protease-induced cytokine release by siRNA
Tryptase at 1 μg/ml, trypsin at 100 ng/ml, SFLLR-NH2 at
100 μM and SLIGKV-NH2 at 100 μM induced 3.0, 2.4, 3.2BMC Cell Biology 2009, 10:62 http://www.biomedcentral.com/1471-2121/10/62
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Effect of siRNA PAR-1.2 on PAR-1 expression in P815 cells Figure 1
Effect of siRNA PAR-1.2 on PAR-1 expression in P815 cells. P815 cells were transfected with siRNA PAR-1.2 for 24, 
48 and 72 h. The PAR-1 expression was determined by real-time quantitative PCR (A), flow cytometry (B), Western blot (C) 
and immunofluorescent analysis (D). In (C) and (D), 1 = 3 nM, 2 = 10 nM and 3 = 30 nM of siRNA PAR-1.2. Values shown are 
mean ± SEM for four to five independent experiments. * P < 0.05 compared with the untransfected control.BMC Cell Biology 2009, 10:62 http://www.biomedcentral.com/1471-2121/10/62
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Effect of siRNA PAR-2.3 on PAR-2 expression in P815 cells Figure 2
Effect of siRNA PAR-2.3 on PAR-2 expression in P815 cells. P815 cells were transfected with siRNA PAR-2.3 for 24, 
48 and 72 h. The PAR-2 expression was determined by real-time quantitative PCR (A), flow cytometry (B), Western blot (C) 
and immunofluorescent analysis (D). In (C) and (D), 1 = 3 nM, 2 = 10 nM and 3 = 30 nM of siRNA PAR-2.3. Values shown are 
mean ± SEM for four to five independent experiments. * P < 0.05 compared with the untransfected control.BMC Cell Biology 2009, 10:62 http://www.biomedcentral.com/1471-2121/10/62
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Effect of siRNA PAR-4.3 on PAR-4 expression in P815 cells Figure 3
Effect of siRNA PAR-4.3 on PAR-4 expression in P815 cells. P815 cells were transfected with siRNA PAR-4.3 for 24, 
48 and 72 h. The PAR-4 expression was determined by real-time quantitative PCR (A), flow cytometry (B), Western blot (C) 
and immunofluorescent analysis (D). In (C) and (D), 1 = 3 nM, 2 = 10 nM and 3 = 30 nM of siRNA PAR-4.3. Values shown are 
mean ± SEM for four to five independent experiments. * P < 0.05 compared with the untransfected control.BMC Cell Biology 2009, 10:62 http://www.biomedcentral.com/1471-2121/10/62
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and 1.7 fold increase in IL-4 release from P815 cells,
respectively at 16 h following incubation (Figure 5A).
However, thrombin at 3 U/ml, RLLFS-NH2 at 100 μM,
VKGILS-NH2 at 100 μM, GYPGQV-NH2 at 100 μM and
VQGPYG-NH2 at 100 μM failed to elicit IL-4 release from
P815 cells following 16 h incubation period (data not
shown). Trypsin induced IL-4 release was almost com-
pletely abolished by 10 nM of siRNA PAR-2.3, and
reduced approximately 65.3% by 10 nM of siRNA PAR-
1.2. Similarly, SLIGKV-NH2  induced IL-4 release was
inhibited by 82.1% and 60.1% by 10 nM of siRNA PAR-
2.3 and siRNA PAR-1.2, respectively. It was observed that
tryptase- induced IL-4 release was eliminated by approxi-
mately 75.3% by 10 nM of siRNA PAR-2.3, and SFLLR-
NH2 induced IL-4 release was diminished by approxi-
mately 79.3% by 10 nM of siRNA PAR-1.2 (Figure 5A).
Tryptase at 1 μg/ml, but not thrombin at 3 U/ml, trypsin
at 100 ng/ml, SFLLR-NH2 at 100 μM, SLIGKV-NH2 at 100
μM and GYPGQV-NH2 at 100 μM was able to provoke 2.1
fold increase in IL-6 secretion from P815 cells at 16 h fol-
lowing incubation. However, siRNA PAR-1.2, siRNA PAR-
2.3 and siRNA PAR-4.3 at 10 nM did not show any effect
on tryptase-induced IL-6 release from P815 cells (Figure
5B).
Discussion
Delivery of synthetic siRNA or vector-based siRNA expres-
sion systems to target cells can reverse the expression and
function of the gene under consideration. In recent years,
siRNA technique has been widely used as one of the most
powerful tools for investigation of protein functions in
mammalian cells [12]. Although P815 cell is a mouse
mastocytoma cell line, rather than primary mast cells, it
has been shown to express PAR-1, PAR-2, PAR-3 and PAR-
4 genes and proteins[13]. To confirm these findings, we
examined the effect of siRNAs on PAR expression in the
present study. Our data showed, for the first time, that siR-
NAs of PAR-1, PAR-2 and PAR-4 are able to reduce PAR-1,
PAR-2 and PAR-4 expression to a great extent, indicating
these small RNAs disrupt the normal PAR generation
process of P815 cells. As for most dsRNAs, siRNAs of PAR-
Effect of siRNA PARs on IL-12 (10 ng/ml) induced expression of PARs in P815 cells Figure 4
Effect of siRNA PARs on IL-12 (10 ng/ml) induced expression of PARs in P815 cells. Cells were transfected with 10 
nM of siRNA PAR-1.2, siRNA PAR-2.3 or siRNA PAR-4.3 for 48 h before IL-12 being added for 6 h at 37°C. The PAR-1 (A), 
PAR-2 (B) and PAR-4 (C) mRNA expression was determined by real-time quantitative PCR. PAR-2 (D) and PAR-4 (E) protein 
expression was analyzed by flow cytometry analysis and expressed as mean fluorescence intensity. Values shown are mean ± 
SEM for four to five independent experiments. * P < 0.05 compared with the response of untransfected cells to the corre-
sponding stimulus.BMC Cell Biology 2009, 10:62 http://www.biomedcentral.com/1471-2121/10/62
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1, PAR-2 and PAR-4 fail to completely block PAR produc-
tion in P815 cells. Incomplete siRNA-induced gene sup-
pression may result from the presence of a fraction of
mRNA in a protected compartment such as spliceosomes,
other nuclear locations or non-transfected cells[14].
Another study found that the activity of siRNA in mam-
malian cells is related to structural target accessibility[15].
PAR-1, PAR-2 and PAR-4 gene silencing can block IL-12
induced alteration of expression of PAR mRNAs and pro-
teins in P815 cells, confirming that IL-12 is an effective
modulator of PAR expression in mast cells. To our knowl-
edge, this is the first work demonstrates the effects of PAR
siRNAs on cytokine induced alteration of PAR expression.
IL-12 regulates Th1 cell differentiation, while suppressing
the expansion of Th2 cell clones[16]. It has been impli-
cated in the pathogenesis of allergy[17]. Since mast cell
has long been recognized as the primary effector cell of
allergy and upregulation of PAR-2 expression was found
in the airways of asthma[18], we anticipate that IL-12 is
likely to be involved in the pathogenesis of asthma
through its ability of regulation of PAR expression on
mast cells.
We have previously showed that tryptase and trypsin can
induce IL-4 release from P815 cells via a PAR-2 dependent
mechanism[13]. Using siRNA technique in the present
study, it is confirmed that trypsin provoked IL-4 release is
mainly through PAR-2 and partially via PAR-1 related
mechanisms, whereas tryptase elicited IL-4 release is
dependent on activation of PAR-2. In contrast, tryptase
induced IL-6 release is independent on the activation of
PARs as siRNAs of PAR-1, PAR-2 and PAR-4 did not show
any influence on the event. Since tryptase is a unique
secretory product of mast cells and IL-4 is a classic Th2
cytokine which is actively involved in the pathogenesis of
allergic reactions, induction of IL-4 release from mast cells
by tryptase may suggest a self-amplification mechanism of
allergic reactions. Inhibition of PAR dependent cytokine
release by siRNAs of PARs has been reported before. Thus,
thrombin induced IL-8 and VEGF release from prostate
cancer cells[19] and IL-6 production from synovial fibrob-
lasts[20] was blocked by siRNA of PAR-1, trypsin induced
IL-8 production from human gastric epithelial cells
(MKN45 cells) was inhibited by siRNA of PAR-2[21]. PAR
independent release of IL-6 from P815 cells induced by
tryptase was unexpected. However, a study demonstrated
Effect of siRNA PARs on IL-4 (A) and IL-6 (B) release from P815 cells Figure 5
Effect of siRNA PARs on IL-4 (A) and IL-6 (B) release from P815 cells. Cells were transfected with 10 nM of siRNA 
PAR-1.2, siRNA PAR-2.3 or siRNA PAR-4.3 for 48 h before protease or agonist of PAR being added for 16 h at 37°C. Values 
shown are mean ± SEM for four to five independent experiments. * P < 0.05 compared with the response of untransfected 
cells to the corresponding stimulus.BMC Cell Biology 2009, 10:62 http://www.biomedcentral.com/1471-2121/10/62
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that beta-tryptase regulates IL-8 expression in airway
smooth muscle cells by a PAR-2-independent mecha-
nism[22] may help to explain our above observation.
Conclusion
In conclusion, siRNAs of PAR-1, PAR-2, PAR-4 not only
block their corresponding PAR expression, inhibit IL-12
induced alteration of expression of PARs, but also reduce
tryptase and trypsin provoked IL-4 release from P815
cells, confirming that mast cell PARs are likely to be
involved in the pathogenesis of allergic reactions. How-
ever, a further study using primary human mast cells
would be better for evaluation the role of mast cell PARs
in allergic reactions.
Methods
Reagents
The mouse mastocytoma cell line P815 was obtained
from the American Type Culture Collection (Manassas,
VA, USA). Cells culture reagents including Dulbecco's
modified Eagle's medium (DMEM) and fetal bovine
serum (FBS) were from HyClone (Logan, UT, USA).
siPORT™ NeoFX™ Transfection Agent was from Ambion
(Huntingdon, UK). TRIZOL Reagent was from Invitrogen
(Carlsbad, CA, USA). ExScriptTM RT reagent kit and
SYBR® Premix Ex Taq TM (perfect real time) was from
TaKaRa (TaKaRa Biotechnology Co. Ltd. DaLian, China).
Primers for mouse PAR-1, PAR-2 and PAR-4 were synthe-
sized by Invitrogen Biotechnology Co. Ltd, (Nanjing,
China). Rabbit anti-mouse PAR-1, PAR-2, PAR-4 and rab-
bit anti-mouse β-actin monoclonal antibody were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). FITC-conjugated goat anti-rabbit polyclonal anti-
body was from BD Pharmingen (San Jose, CA, USA). Para-
formaldehyde, bovine serum albumin (BSA, fraction V),
trypsin, thrombin and peroxidase conjugated goat anti-
rabbit immunoglobulins were from Sigma Inc. (St. Louis,
MO, USA). Recombinant human lung β-tryptase was from
Promega (Madison, WI, USA). Agonist peptides of PARs,
as well as their reverse forms were synthesized in CL Bio-
Scientific Inc (XiAn, China). The sequences of the active
and reverse peptides were: PAR-1, SFLLR-NH2 and RLLFS-
NH2; PAR-2, SLIGKV-NH2  and VKGILS-NH2; PAR-4,
GYPGQV-NH2 and VQGPYG-NH2. Mouse IL-4 and IL-6
ELISA kits were from Pierce Biotechnology Inc. (Rockford,
IL, USA). Most of other reagents such as salt and buffer
components were analytical grade and obtained from
Sigma.
Small interfering RNA synthesis
The potential siRNAs of PAR-1, PAR-2 and PAR-4 were
designed by using the prediction of single strand domains
in the secondary mRNA structure and subsequent negative
BLAST analyses, 3 sequences for each PAR (Table 1). A
scrambled sequence was used as negative control, and β-
actin siRNA was employed as positive control. No signifi-
cant matching in mouse transcripts was found in BLAST
analyses. siRNA were prepared by in vitro transcription
using the siPORT™ NeoFX™ Transfection Agent, a lipid-
based agent for reverse transfection.
P815 cell culture
Cells were cultured with ATCC complete growth medium
including DMEM with 4 mM L-glutamine, 1.5 mg/ml
sodium bicarbonate, 4.5 mg/ml glucose, 10% FBS, 100 U/
ml penicillin and 100 μg/ml streptomycin in 75-cm2 tis-
sue culture flasks (Falcon) at 37°C in a 5% (v/v) CO2,
water-saturated atmosphere.
Cell transfection
The cell transfection was performed according to the man-
ufacturer's instruction. Briefly, P815 cells were collected 1
h before transfection. After washing, cells were resus-
pended in normal growth medium to a concentration of
1 × 105 cells/ml at 37°C. For preparation of the transfec-
tion solution, 3 μl of siPORT NeoFX Transfection agent
was added into OPTI-MEM I medium to a total volume of
50 μl, and the solution was incubated for 10 min at room
temperature. After dilution of small RNA in OPTI-MEM I
medium to final concentrations of 3, 10, 30 and 100 nM,
the RNA preparations were mixed with transfection solu-
tion for 10 min at room temperature. The RNA transfec-
tion mixture was then dispensed into a 12-well culture
plate, 100 μl per well before 900 μl of cell suspension
Table 1: siRNA sequences of PARs
Sequence Sense strand (5'-3') Antisense strand (5'-3')
PAR-1.1 GGGUAGGGCAGUCUACUUAtt UAAGUAGACUGCCCUACCCtc
PAR-1.2 GGUUCCAUGAGAAAAGGUUtt AACCUUUUCUCAUGGAACCtt
PAR-1.3 CCAAGUGUAUUUCACAUAAtt UUAUGUGAAAUACACUUGGtc
PAR-2.1 GCUGUACCUGAGGAUGUCAtt UGACAUCCUCAGGUACAGCtc
PAR-2.2 GCAUCAGUAUCAGAAACUGtt CAGUUUCUGAUACUGAUGCtt
PAR-2.3 CCAACCAAACAAAAACUACtt GUAGUUUUUGUUUGGUUGGtt
PAR-4.1 CCCUCAGGACAUGACCUUAtt UAAGGUCAUGUCCUUGAGGGtt
PAR-4.2 CCUUCAUUAGUGGAGCUGAtt UCAGCUCCACUAAUGAAGGtc
PAR-4.3 CGCCUCACUACUGGACUCUtt AGAGUCCAGUAGUGAGGCGttBMC Cell Biology 2009, 10:62 http://www.biomedcentral.com/1471-2121/10/62
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being added into each well. The transfected cells were cul-
tured in the normal cell culture conditions for 24, 48 and
72 h before their total RNA being extracted as described
above. Control cells were not transfected but processed
following a similar procedure.
Quantitative real-time PCR analysis of PAR mRNAs
Total RNA was isolated by using a TRIZOL reagent kit
according to the manufacturer's instructions and stored at
-80°C. Reverse transcription was performed by using a
commercial RNA-PCR kit according to the manufacturer's
instructions. Briefly, 1 μg of total RNA was reverse tran-
scribed in 20 μl of solution containing 50 μM of oligo-d
(T) as a primer, 10 mM of dNTP mixture, 100 U of AMV,
20 U of RNase inhibitor and 4 μl of 5 × AMV buffer. The
mixture was incubated at 42°C for 30 min and 95°C for
3 min. After synthesizing cDNA from 5 μg of total RNA by
using ExScriptTM RT reagent kit, quantitative PAR-1, PAR-
2 and PAR-4 mRNA expression in P815 cells was deter-
mined by real-time PCR with an ABI Prism 7700 Sequence
Detection System (Perkin Elmer Applied Systems, Foster
City, CA, USA) following the manufacture's protocol.
Each reaction contains 12.5 μl of 2 × SYBR green Master
Mix, 300 nM oligonucleotide primers (Table 2), 10 μl of
the cDNA (1 in10 dilution) or plasmid DNA and water, to
a total of 25 μl. The thermal cycling conditions included
an initial denaturation step at 95°C for 2 min, 40 cycles at
95°C for 30 s, 60°C for 30 s, and 72°C for 30 s. The RT-
PCR expression of the target gene was presented as a ratio,
normalized to an endogenous reference β-action and rel-
ative to a calibrator (control untransfected cells) [23].
Western blot analysis
Cells were lyzed by using Triton X-100 lysis buffer for 15
min in the presence of 2 mM sodium orthovanadate, 1
mM EDTA, 50 g/ml aprotinin, 100 M leupeptin, 1 mM
Dithio-DL-Treitol (DTT) and 1 mM amino-ethyl-benze-
nesul-fonylfuoride hydrochloride (AEBSF). After centrifu-
gation at 1500 g for 5 min, the supernatant was mixed
with β-mercaptoethanol for electrophoresis on a 12% acr-
ylamide reducing gel. The proteins on the gel were then
transferred to Immobilon PVDF membranes. The mem-
branes were blocked overnight at 4°C with 1% BSA in
Tris-buffered saline (TBS) containing 0.05% Tween 20
before rabbit anti-mouse PARs (1:500) being added for 2
h at 37°C. After washing with TBS, the membranes were
incubated with peroxidase conjugated goat anti-rabbit
immunoglobulins antibody (1:2000) for 1 h at 37°C, and
the membranes were developed with DakoCytomation
Liquid DAB + Substrate. Not transfected cells were used as
negative control.
Flow cytometry analysis
P815 cells were pelleted by centrifugation at 800 g for 5
min, and fixed with 4% Paraformaldehyde (VWR interna-
tional) for 30 min on ice before being washed twice with
0.5% BSA. The cells were resuspended in PBS and incu-
bated with FITC-conjugated rabbit anti-mouse PAR-1,
PAR-2, PAR-4 polyclonal antibody or isotype control (at a
final concentration 4 μg/ml) at 37°C for 2 h. Cells were
finally resuspended in PBS and analyzed on a FACS Cali-
bur flow cytometer with CellQuest software (BD Bio-
sciences).
Immunofluorescence cell staining
After being fixed in 4% paraformaldehyde for 30 min,
P815 cells were incubated with 1% BSA for 10 min. After
washing, the cells were resuspended in PBS and incubated
with FITC-conjugated rabbit anti-mouse PAR-1, PAR-2,
PAR-4 polyclonal antibody or isotype control (at a final
concentration 4 μg/ml) at 37°C for 2 h. Images were
obtained on a Nikon EZ-C1 confocal laser scanning
microscope (Japan).
Mast cell challenge
P815 cells at a density of 1 × 105 cells/ml were transfected
with 10 nM of siRNAs of PAR-1, PAR-2 or PAR-4 for 48 h
at 37°C before PAR expression being examined. The trans-
fected cells were then exposed to IL-12 (10 ng/ml), trypsin
(100 ng/ml, 1 μg/ml = 42 nM), tryptase (1 μg/ml, 1 μg/ml
= 7.4 nM), thrombin (3 U/ml, 1 U/ml = 6.7 nM), the ago-
nist peptides of PARs (Table 3), as well as the reverse pep-
tides (100 μM), respectively. At 6 or 16 h following
challenge, the culture plates were centrifuged at 800 g for
5 min at 4°C and culture supernatants (1 ml per well)
were collected and stored at -80°C until use. The cell pel-
Table 2: Primer sequences for real time PCR analysis
Primer Sequence Size of product (bp)
PAR-1 forward 5'-GTTGATCGTTTCCACGGTCT-3' 225 bp
reverse 5'-ACGCAGAGGAGGTAAGCAAA-3'
PAR-2 forward 5'-CACCTGGCAAGAAGGCTAAG-3' 298 bp
reverse 5'-CCCAGGGTTACTGACGCTAA-3'
PAR-4 forward 5'-GCAGACCTTCCGATTAGCTG-3' 292 bp
reverse 5'-AGGGCTCGGGTTTGAATAGT-3'
β-actin forward 5'-GCTACAGCTTCACCACCACAG-3' 288 bp
reverse 5'-GGTCTTTACGGATGTCAACGTC-3'BMC Cell Biology 2009, 10:62 http://www.biomedcentral.com/1471-2121/10/62
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let was resuspended in PBS and analyzed on a FACS Cali-
bur flow cytometer and confocal laser scanning
microscope. Concentrations of IL-4 and IL-6 in the super-
natants were quantified using commercial ELISA kits
according to the manufacturer's instructions.
Statistical analyses
Data are expressed as mean ± SEM for the indicated
number of independently performed duplicated experi-
ments. Statistical significance between means was ana-
lyzed by one-way ANOVA or the Student's t test utilizing
the SPSS 13.0 version. P < 0.05 was taken as statistically
significant.
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